Maa: Etelä-Afrikka
Kieli: englanti
Lähde: South African Health Products Regulatory Authority (SAHPRA)
Knoll
TARKA® capsules SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): TARKA ® capsules COMPOSITION: Each TARKA capsule contains 180 mg verapamil hydrochloride and 2 mg trandolapril . PHARMACOLOGICAL CLASSIFICATION: A 7.1.3 Other hypotensives. PHARMACOLOGICAL ACTION: TARKA capsules contain the pro-drug trandolapril, a non peptide angiotensin converting enzyme (ACE) inhibitor with a carboxyl group but without a sulphydryl group and verapamil, a calcium ion influx inhibitor (slow channel blocker or calcium ion antagonist). Verapamil exerts its pharmacological effects by modulating the influx of ionic calcium across the cell membrane of the arterial smooth muscle as well as in conductile and contractile myocardial cells. Verapamil reduces myocardial oxygen consumption in vitro directly by intervening in the energy consuming metabolic processes of the myocardial cell, and indirectly by diminishing the peripheral resistance (afterload). It prolongs impulse conduction in the AV node. Trandolapril is rapidly absorbed in the fasting state and then non-specifically hydrolysed to its active metabolite, trandolaprilat. Trandolapril binds tightly and in a saturable manner to ACE. The administration of trandolapril causes decreases in the concentrations of angiotensin II, aldosterone and atrial natriuretic factor and increases in plasma renin activity and concentrations of angiotensin I. Trandolapril thus modulates the renin-angiotensin-aldosterone system which plays a major part in regulating blood volume and blood pressure. The blood pressure lowering effect is evident after 1 hour, with a peak effect between 8 and 12 hours. The antihypertensive effect persists for at least 24 hours. Tarka: Neither animal studies nor healthy volunteer studies could demonstrate pharmacokinetic or renin-angiotensin Lue koko asiakirja